---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-060044"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T13:12:04.888850+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics appoints Brendan Hannah as principal financial officer after Ted Monohon resigns

## Summary
- Ted Monohon resigns as Chief Accounting Officer and VP of Finance, effective March 16, 2023; no disagreement with company.
- Brendan Hannah, current Chief Business Officer, appointed as principal financial officer and principal accounting officer effective March 16, 2023.
- Hannah's compensation unchanged; no family relationships or reportable transactions.

## SEC filing metadata
- accession: 0001193125-23-060044
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/0001193125-23-060044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/d146910d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-060044
- JSON: https://secwatch.observer/filing/0001193125-23-060044.json
- Plain text: https://secwatch.observer/filing/0001193125-23-060044.txt

## Key facts
- Executive change
  Ted Monohon resigned as Chief Accounting Officer and Vice President of Finance at Quince Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Accounting Officer and Vice President of Finance
  source text: On March 1, 2023, Ted Monohon informed Quince Therapeutics, Inc. (the “ Company ”) of his intention to resign from his position as the Chief Accounting Officer and Vice President of Finance, including as the principal financial officer and principal accounting officer, effective as of March 16, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/0001193125-23-060044-index.htm
- Executive change
  Brendan Hannah was appointed as principal financial officer and principal accounting officer at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: On March 3, 2023, the Board of Directors of the Company appointed Brendan Hannah, Chief Business Officer of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of March 16, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523060044/0001193125-23-060044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.